Guangzhou Virotech Pharmaceutical Co., Ltd.
6 clinical trials · Sponsor
◉ Watch Guangzhou Virotech Pharmaceutical Co., Ltd.
| Record | Firm | Date |
|---|---|---|
| A Study of VRT106, Combined With Camrelizumab, and Apatinib for Advanced HCC (NCT07589244) | Guangzhou Virotech Pharmaceutical Co., Ltd. | 2026-05-13 |
| A Study of VRT106 in Combination With Radiotherapy in Adult Patients With Diffuse Midline Glioma / Diffuse Intrinsic Pontine Glioma (NCT07589257) | Guangzhou Virotech Pharmaceutical Co., Ltd. | 2026-05-07 |
| A Study of VRT106 for Injection in Patients With Recurrent/Progressive Glioblastoma (NCT07093814) | Guangzhou Virotech Pharmaceutical Co., Ltd. | 2025-09-02 |
| A Study of Intravenous VRT106 for Locally Advanced or Metastatic Solid Tumors (NCT06826313) | Guangzhou Virotech Pharmaceutical Co., Ltd. | 2025-03-19 |
| A Study of Intravenous M1-c6v1 for Locally Advanced or Metastatic Solid Tumors (NCT06046742) | Guangzhou Virotech Pharmaceutical Co., Ltd. | 2024-07-10 |
| A Study of Recombinant Oncolytic Virus M1(VRT106) in Patients With Solid Tumors (NCT06368921) | Guangzhou Virotech Pharmaceutical Co., Ltd. | 2024-06-19 |
Track Guangzhou Virotech Pharmaceutical Co., Ltd. automatically
Every clearance here is in the API, with alerts when new ones post.